TNF and inflammatory bowel disease: By downregulating pro-inflammatory cytokines such as TNF-α and IL-1β or enhancing the production of anti-inflammatory mediators like IL-10, gene therapy could theoretically achieve better control of inflammation in IBD patients, potentially reducing the reliance on immunosuppressive drugs [74].